2m 2m 2m 2m 2m 2m 2m
DENALI THERAPTCS (DNLI)
NASDAQ
$24.77+$0.72 (+3.01%)
Price as of Jun 23, 2026 6:24 PM EDT- $3.8BMarket Cap
- 76.58%1-Year Change
- BiotechnologyIndustry
DENALI THERAPTCS (DNLI)
$24.77+$0.72 (+3.01%)
Annual
Quarterly
12/31/2025 | 12/31/2024 | 12/31/2023 | 12/31/2022 | ||
|---|---|---|---|---|---|
Income Statement | |||||
Total Operating Revenue | 0 N/A | 0 -100.00% | 330.5M +204.74% | 108.5M +122.90% | |
Cost of Revenue | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Gross Profit | 0 N/A | 0 -100.00% | 330.5M +204.74% | 108.5M +122.90% | |
Sales and Marketing Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Research and Development Expense | -418.8M +5.63% | -396.4M -6.47% | -423.9M +18.16% | -358.7M +35.19% | |
Depreciation and Amortization Expense | 11.2M +43.46% | 7.8M -53.40% | 16.7M +61.09% | 10.4M +20.83% | |
Total Operating Expenses | 555.3M +10.65% | 501.9M -4.81% | 527.2M +17.37% | 449.2M +30.43% | |
Operating Profit | -555.3M +13.95% | -487.3M +147.76% | -196.7M -42.27% | -340.7M +15.21% | |
Interest Income | 42.9M -33.62% | 64.6M N/A | N/A N/A | N/A N/A | |
Interest Expense | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Interest Income and Expense and Net | 42.9M -33.62% | 64.6M N/A | 0 N/A | 0 N/A | |
Total Nonoperating Income and Expense | N/A N/A | N/A N/A | 51.5M +248.62% | 14.8M +221.52% | |
Income before Taxes | -512.4M +21.23% | -422.7M +191.13% | -145.2M -55.46% | -326.0M +11.96% | |
Income Taxes | 102,000 +50.00% | 68,000 +126.67% | 30,000 +42.86% | 21,000 +103.65% | |
Extraordinary Items | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Net Income | -512.5M +21.23% | -422.8M +191.12% | -145.2M -55.45% | -326.0M +12.19% | |
Net Income from Continuing Operations Applicable to Common | -512.5M +21.23% | -422.8M +191.12% | -145.2M -55.45% | -326.0M +12.19% | |
Basic EPS and Net Income | -2.97 +15.56% | -2.57 +142.45% | -1.06 -59.23% | -2.60 +8.79% | |
Diluted EPS and Net Income | -2.97 +15.56% | -2.57 +142.45% | -1.06 -59.23% | -2.60 +8.79% | |
Basic Weighted Average Shares | 172.6M +4.97% | 164.5M +19.73% | 137.4M +9.43% | 125.5M +3.30% | |
Diluted Weighted Average Shares | 172.6M +4.97% | 164.5M +19.73% | 137.4M +9.43% | 125.5M +3.30% | |
Balance Sheet | |||||
Cash and Cash Equivalents | 205.3M +17.36% | 175.0M +37.65% | 127.1M -41.71% | 218.0M -25.70% | |
Short-Term Investments | 662.6M +0.79% | 657.4M -27.55% | 907.4M -18.85% | 1.1B +95.51% | |
Cash and Cash Equivalents and Short-Term Investments | 867.9M +4.27% | 832.3M -19.54% | 1.0B -22.58% | 1.3B +54.40% | |
Total Current Assets | 900.7M +4.19% | 864.4M -18.77% | 1.1B -22.46% | 1.4B +52.95% | |
Accumulated Depreciation | 62.9M +20.85% | 52.0M +13.13% | 46.0M +23.61% | 37.2M +26.82% | |
Property and Plant and Equipment and Net | 52.4M -5.13% | 55.2M +21.16% | 45.6M +3.41% | 44.1M +13.44% | |
Total Long-Term Assets | 25.9M +4.84% | 24.7M +36.37% | 18.1M +35.41% | 13.4M +12.87% | |
Total Assets | 1.1B -16.69% | 1.4B +19.09% | 1.2B -20.98% | 1.5B +3.99% | |
Income Taxes Payable | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Short-Term Debt | N/A N/A | N/A N/A | N/A N/A | 4.4M N/A | |
Total Current Liabilities | 98.4M -3.77% | 102.2M +31.07% | 78.0M -78.57% | 363.9M -3.79% | |
Total Long-Term Debt | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Total Long-Term Liabilities | 27.2M -25.80% | 36.7M N/A | 0 -100.00% | 379,000 0.00% | |
Total Liabilities | 131.1M -9.28% | 144.5M +17.51% | 123.0M -70.57% | 417.8M -5.44% | |
Retained Earnings | -2.1B +33.30% | -1.5B +37.88% | -1.1B +14.96% | -971.0M +50.54% | |
Total Stockholders Equity | 1.0B -17.56% | 1.2B +19.28% | 1.0B -1.10% | 1.0B +8.33% | |
Total Shares Outstanding | 156.2M +8.29% | 144.2M +4.22% | 138.4M +1.78% | 136.0M +11.19% | |
Cash Flow | |||||
Cash from Operating Activities | -412.6M +18.67% | -347.7M -2.88% | -358.0M +46.29% | -244.7M +15.77% | |
Capital Expenditures | 9.5M -40.28% | 15.9M +22.98% | 12.9M -27.44% | 17.8M +109.80% | |
Cash from Investing Activities | 255.3M +387.62% | -88.8M -135.60% | 249.3M +276.33% | -141.4M +553.78% | |
Dividends Paid | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Cash from Financing Activities | 189.2M -60.93% | 484.3M +2,617.76% | 17.8M -94.26% | 310.7M +1,505.70% | |
Financials Ratio | |||||
Gross Margin | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Operating Margin | N/A N/A | N/A N/A | -59.51% -81.06% | -314.16% -48.31% | |
Return on Assets | -40.69% +21.67% | -33.45% +201.03% | -11.11% -51.19% | -22.76% +17.83% | |
Return on Equity | -45.69% +22.16% | -37.40% +167.00% | -14.01% -56.93% | -32.52% +18.24% | |
Revenue Growth | N/A N/A | -100.00% -148.84% | 204.74% +66.60% | 122.90% +243.73% | |
Current Ratio | 9.16 +8.28% | 8.46 -38.02% | 13.65 +261.87% | 3.77 +58.97% | |
Cash Ratio | 2.09 +21.96% | 1.71 +5.02% | 1.63 +172.01% | 0.60 -22.77% | |
Debt-to-Equity Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Debt-to-Assets Ratio | N/A N/A | N/A N/A | N/A N/A | N/A N/A | |
Earnings & Revenue History
Debt-to-Assets
Cash Flow